GSK flash­es pos­i­tive da­ta for Tesaro drug that could be­come 7th ap­proved PD-(L)1

A dark horse as­set from Glax­o­SmithK­line’s $5.1 bil­lion buy­out of Tesaro is out with its first batch of da­ta in over a year — promis­ing da­ta that could line up the British drug­mak­er for the 7th FDA ap­proved PD-1 drug, al­though it’s not clear when.

When GSK pur­chased the Waltham-based can­cer biotech in De­cem­ber of 2018, con­ver­sa­tion fo­cused right­ly on Ze­ju­la, the al­ready-ap­proved PARP in­hibitor, and whether the new ex­ec­u­tive crew of Hal Bar­ron and Em­ma Walm­s­ley were right in their as­ser­tion that the drug could both ri­val As­traZeneca’s Lyn­parza and have util­i­ty in more than just ovar­i­an can­cer. But Tesaro al­so brought a cou­ple of oth­er clin­i­cal stage as­sets. Chief among them: a PD-1 in­hibitor called dostar­limab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.